Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

With the growing demand for GLP-1 drugs for weight loss, a high percentage of medication users are experiencing temporary and long-term side effects from these rapid weight loss methods. Kelker Pharma ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals.

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

US drugmaker Eli Lilly enjoyed a good day on the obesity front on Wednesday, with the news that its GLP-1 receptor agonist tirzepatide - branded as Wegovy and Mounjaro - outscored its main rival from ...

An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.